Logan H. Sigua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Logan H. Sigua has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Jun Qi
Department of Cancer Biology Dana‐Farber Cancer Institute Boston MA USA
17 shared publications - Alexander Beck
Center for Neuropathology, Ludwig-Maximilians-University, 81377 Munich, Germany
15 shared publications - Amy Goodale
Broad Institute, Cambridge, MA, USA
15 shared publications - Amy Saur Conway
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
15 shared publications - Andrew Groves
Harvard Medical School Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Boston, Massachusetts
15 shared publications - Angel Montero Carcaboso
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, Spain
15 shared publications
Latest Publications
- Open Access
- 3 January 2026
- Published by Elsevier in World Neurosurgery
- Vol. 206, 124785
Circumferential Minimally Invasive Adult Spinal Deformity Surgery: A Systematic Review With Key Concepts and Technical Considerations
- 3 January 2026
- Published by Elsevier in World Neurosurgery
- Vol. 206, 124785
Open AccessCircumferential Minimally Invasive Adult Spinal Deformity Surgery: A Systematic Review With Key Concepts and Technical Considerations
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma